RE:RE:RE:RE:RE:RE:Others are getting FDA Approval Once Again when there is a chance to denigrate Sona or to make appear superior a competitor product up pop THEE ROOK and his colleagues. They will use any means to try to confuse.
YESTERDAY when he wanted to make Quidel look better than Sona he called Quidel a BIG COMPANY and an ESTABLISHED COMPANY.
TODAY when he wants Abbott to look better than Quidel he calls Quidel a RUNT COMPANY.
He could not make his BIAS more obvious and that reflects on his opinions and posts.
This Abbott test is yet another example of why we need a LEVEL PLAYING FIELD to follow on from yesterdays´ discussion.
Abbott have selectively used a high-viral load, symptomatic population to produce high accuracy figures. Why? Why haven´t they tested Asymtomatic?
They then use Executive Double Talk to create an inflated impression of their product.
The test, BinaxNOW COVID-19 Ag Card, could be used to check that people participating in larger gatherings, such as those returning to schools or workplaces, do not have Covid-19 and could help aid the reopening of the U.S., the executives said.
Why did the executives say that it COULD be used in these groups and that it COULD help aid reopening?
Why not CAN or WILL?
Because they DO NOT have any evidence to back that up.
They have NO ASYMPTOMATIC TESTING so don´t have any idea how their test will work In-Field.
At the moment they have a test that relies on laboratory back-up and cannot be used for Mass Screening.